Parexel reaches first milestone in Microsoft alliance, more coming soon

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Rawpixel)
(Image: Getty/Rawpixel)
Parexel has launched its first offering as part of its alliance with Microsoft, through which the companies are looking to redefine the life sciences industry, says CRO.

The Waltham, MA-based contract research organization (CRO) Parexel announced the partnership in October​ of this year at which time Xavier Flinois, president of Parexel Informatics told us the alliance “is completely transformational​.”

Since announcing the partnership, the companies have been working to develop a roadmap of innovative, patient-centric technologies and cloud-based services to support clinical research and market access for global life science clients, Paul Bidez, vice president of Regulatory and Clinical Solutions for Parexel told us.

The first offering to result from the partnership is the Perceptive Cloud, which the company said combines Parexel’s technology solutions with Microsoft’s intelligent cloud services and investment in global compliance certifications and enterprise-grade security. 

Together we are committed to enhancing the user experience and truly redefining the life sciences industry​,” Bidez explained. “The Perceptive Cloud is only the first step in this effort​.”

The Perceptive Cloud platform aims to automate workflows and provide greater access to data in order to simplify drug development. The platform includes: LIQUENT InSight Regulatory Information Management (RIM), Study Start-Up, DataLabs Electronic Data Capture (EDC), Managed Access Programs, and IMPACT Clinical Trial Management (CTMS).

New offerings will be announced over the coming months, said Bidez.

The explosion of data is rapidly changing many industries, including healthcare​,” he added.

The cloud computing model enables efficiencies through a shared data platform, while addressing the significant privacy, security and compliance challenges that the pharmaceutical industry faces​.”

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers